The Effects of Colony-Stimulating Factor-1 on the Distribution of Mononuclear Phagocytes in the Developing Osteopetrotic Mouse

By Philip Roth, Melissa G. Dominguez, and E. Richard Stanley

Colony-stimulating factor-1 (CSF-1), the primary regulator of mononuclear phagocyte (Mφ) production, exists as either a circulating or cell surface, membrane-spanning molecule. To establish transplacental transfer of maternal CSF-1, gestational day-17 mothers were injected intravenously with 125I-mouse CSF-1 or human rCSF-1, and the 125I-cpm or human CSF-1 concentrations were measured in fetal tissue, placenta, and fetal/maternal sera. Biologically active CSF-1 crossed the placenta and peaked in fetal tissue, placenta, and serum 10 minutes after injection. The role of CSF-1 in perinatal Mφ development was examined by studying the CSF-1-deficient osteopetrotic (csfmop/csfmop) mouse. Fetal/neonatal mice, derived from matings of either +/csfmop females with csfmop/csfmop males or the reciprocal pairings, were genotyped and tissue Mφ identified and quantified. In the presence of circulating maternal CSF-1 (+/csfmop mother), Mφ development in csfmop/csfmop liver was essentially complete at birth relative to +/csfmop littermates, but significantly reduced in spleen, kidney, and lung. In the absence of circulating maternal CSF-1 (csfmop/csfmop mother), Mφ numbers at birth were reduced in csfmop/csfmop liver relative to the offspring of +/csfmop mothers, but were similar in spleen, kidney, and lung. We conclude that CSF-1 is required for the perinatal development of most Mφ in these tissues. Compensation for total absence of local CSF-1 production by circulating, maternal CSF-1 is tissue-specific and most prominent in liver, the first fetal organ perfused by placental blood. However, because some Mφ developed in the complete absence of CSF-1, other factors must also be involved in the regulation of macrophage development.

A useful model for the study of the biologic role of CSF-1 is the osteopetrotic (csfmop/csfmop) mutant mouse, which is deficient in bone resorption due to a paucity of bone osteoclasts; has markedly reduced bone marrow macrophages, blood monocytes, and serosal macrophages; displays defects in both male and female fertility (reviewed in Pollard and Stanley); and exhibits abnormalities in neural processing. These abnormalities are the result of a null mutation in the CSF-1 gene caused by a single thymidine insertion in exon 4 leading to a frame-shift at base pair 262 with translational termination 21 bp downstream. The resultant 63 amino acid truncated translation product is totally devoid of biological activity. The csfmop/csfmop mouse has been extremely helpful in defining mononuclear phagocyte populations that are dependent on CSF-1 for their development. Administration of CSF-1 to newborn csfmop/csfmop mice cured their osteopetrosis and substantially corrected the deficiencies in osteoclasts, bone marrow cellularity, and blood monocytes, although having little effect on resident macrophages at serosal surfaces. These observations suggest that dependence on circulating CSF-1 for development is limited to specific macrophage populations. In fact, a detailed analysis of the postnatal development of various tissue macrophage populations in csfmop/csfmop mice and their normal littersmates indicates that...
distinct populations may be subject to complete dependence on, partial dependence on, and complete independence of CSF-1 for their development and maintenance. In general, macrophages in tissues, which undergo significant remodelling and morphogenesis during the perinatal period, seemed most dependent on CSF-1 and failed to develop in csfmop/csfmop mice. These cells are thought to act like osteoclasts as scavengers or produce trophic factors in these tissues, such as the dermis and synovial membranes, which are hypoplastic and hypotrophic in mutant csfmop/csfmop mice, and testes, in which the function of closely associated Leydig cells is affected in csfmop/csfmop mice. In contrast, the appearance of macrophages, which are important in immunologic and inflammatory responses, in the epidermis (Langerhans cells), thymus, and lymph node is independent of CSF-1.16,29-31 Because csfmop/csfmop mice are totally devoid of CSF-1, they are well suited to study the role of this growth factor in the appearance of macrophages during perinatal development.

In the present study, we demonstrate that maternal CSF-1 crosses the placenta and that CSF-1 is required for the perinatal development of most macrophages in liver, spleen, kidney, and lung. We also show that circulating maternal CSF-1 can compensate for the absence of embryonic/fetal CSF-1 in csfmop/csfmop fetuses and regulate normal macrophage development in liver but not spleen, kidney, or lung.

MATERIALS AND METHODS

Animals. C57BL/6 mice were obtained from the National Cancer Institute and housed in the animal care facility of the Albert Einstein College of Medicine according to established guidelines. Osteopetrotic csfmop/csfmop mice,16 and testes, in which the function of closely associated Leydig cells is affected in csfmop/csfmop mice.16,17,18 In addition, the presence or absence of CSF-1 was used to distinguish +/csmop and csmop/csmop mice, respectively. Alternatively, PCR was used to amplify the segment of exon 4 containing the op mutation in DNA purified from the tails of fetal and neonatal mice, as previously described.14,15

RESULTS

Transplacental transfer of CSF-1. To determine whether CSF-1 is transferred across the placenta, trace amounts of 125I-CSF-1 labeled to high specific activity were administered intravenously to pregnant female mice on day 17 of gestation. Results of a representative experiment demonstrating 125I-cpm transferred to whole fetuses and placentas are shown in Table 1. At 10 minutes postinjection, approximately 5% of the injected cpm was transferred across the placenta to the 10 fetuses in this particular experiment. Determination of immunoprecipitable counts (due to intact 125I-CSF-1 only) showed that approximately 30% of fetuses-associated cpm were due to intact growth factor (data not shown). This observation is not surprising in

From www.bloodjournal.org by guest on September 24, 2017. For personal use only.
To confirm that biologically active CSF-1 was, in fact, transferred across the placenta, day-17 gestation pregnant female mice were injected intravenously with human recombinant CSF-1, which also interacts with mouse CSF-1 receptors. The mice were killed at various times after injection and growth factor levels were measured in placental and fetal tissues by a radioimmunoassay that detects only biologically active growth factor levels. As shown in the representative experiment in Fig. 1A, biologically active CSF-1 was already detectable at 1 minute, peaked at 10 minutes, and was still detectable at 24 hours after injection in both fetal and placental tissues. Placental CSF-1 concentrations on a wet tissue weight basis exceeded those in the fetus from 1 to 120 minutes by 7.4- to 13.2-fold. Interestingly, the amount of human CSF-1 transferred to each fetus corresponds closely to the amount predicted from 125I-CSF-1 experiments. Because each fetus weighs approximately 550 mg (Roth and Stanley, unpublished data), the peak human CSF-1 concentration of 100 pg/mg fetal tissue corresponds to 55 ng/fetus, which equals 0.46% of the injected dose of 12 µg. Although virtually identical to the 0.5% of the injected dose predicted by the 125I-CSF-1 experiments (Table 1), it represents a fourfold increase in biologically active (immunoreactive) CSF-1, which is not surprising considering the rapid saturation of maternal clearance and degradation of CSF-1 by the liver at elevated circulating CSF-1 concentrations. Examination of pooled sera (Fig 1B) again showed detectable CSF-1 at 1 minute, peak values at 10 minutes, and levels that could still be detected at 24 hours in both maternal and fetal sera. Although following similar kinetics, large differences were apparent between circulating levels in the maternal and fetal animals in this representative and other similar experiments.

**Appearance of F4/80-positive macrophages in perinatal tissues.** To assess the role of circulating CSF-1 in the development and maintenance of F4/80-positive macrophages, several representative tissues were studied in csfm⁻/⁻/csfm⁻/⁻ mice and their normal +/csfm⁺ littersmates born to both phenotypically normal +/csfm⁺ females (with normal levels of circulating CSF-1 available for transplacental passage) and csfm⁻/⁻/csfm⁻/⁻ mothers (with no circulating CSF-1).

**Liver.** In animals born to +/csfm⁺ mothers, F4/80-positive cells were present at the earliest time points studied (Fig 2A) in both csfm⁻/⁻/csfm⁻/⁻ and +/csfm⁺ offspring. Whereas the densities of F4/80-positive cells were somewhat diminished in csfm⁻/⁻/csfm⁻/⁻ mice compared with their +/csfm⁺ littersmates during fetal life (gestational days 13 and 15), there was no difference shortly after birth (postnatal day 1). However, during the first postnatal week, F4/80-positive liver macrophages continue to increase in the +/csfm⁺ mice, in contrast to the csfm⁻/⁻/csfm⁻/⁻ mice, in which they have plateaued.

As was the case for the offspring of +/csfm⁺ females, F4/80-positive cells were present at the earliest time points studied in both csfm⁻/⁻/csfm⁻/⁻ and +/csfm⁺ mice born to csfm⁻/⁻/csfm⁻/⁻ mothers (Fig 2B). Although csfm⁻/⁻/csfm⁻/⁻ mice had diminished liver macrophage densities compared with their +/csfm⁺ littersmates during fetal life, they also had reduced numbers shortly after birth (postnatal day 1), in contrast to the situation observed for the offspring of +/csfm⁺ females (Fig 2A). Once again, the density of F4/80-positive cells in +/csfm⁺...
mice increased over the first week of life; but, surprisingly, the density of these cells on postnatal day 7 in $\text{csfm}^{op}/\text{csfm}^{op}$ mice relative to that observed in $\text{csfm}^{op}$ littermates was 70%, which was very similar to the relationship observed in the offspring of $\text{csfm}^{op} / \text{csfm}^{op}$ females. Interestingly, $\text{csfm}^{op}$ fetal mice growing in $\text{csfm}^{op}/\text{csfm}^{op}$ mothers appeared to have higher densities of F4/80-positive cells between gestational days 13 and 15 than those growing in $\text{csfm}^{op}$ mothers.

Despite the differences described above, the histologic appearance of F4/80-positive cells in the livers of $\text{csfm}^{op}/\text{csfm}^{op}$ and $\text{csfm}^{op}$ mice did not depend on whether they were the offspring of $\text{csfm}^{op}$ or $\text{csfm}^{op}/\text{csfm}^{op}$ mothers (data not shown). In both $\text{csfm}^{op}$ and $\text{csfm}^{op}/\text{csfm}^{op}$ neonatal livers, F4/80-positive cells were dendritic and intimately associated with islands of hematopoietic cells (Fig 3a and b). However, there was an obvious reduction in the density of F4/80-positive cells in the neonatal $\text{csfm}^{op}/\text{csfm}^{op}$ liver (Fig 3b).

**Spleen.** Although F4/80-positive cells were detectable in the spleens of both $\text{csfm}^{op}/\text{csfm}^{op}$ and $\text{csfm}^{op}$ mice during fetal life, they were present at extremely low levels (Fig 4). In the $\text{csfm}^{op}$ offspring of $\text{csfm}^{op}$ mothers, splenic F4/80-positive macrophages steadily increased in density over the first week of life. In $\text{csfm}^{op}/\text{csfm}^{op}$ offspring, although positive cells were present in substantial numbers, they were significantly lower in density compared with $\text{csfm}^{op}$ littermates at birth (postnatal day 1) and during the first week of life (Fig 4A). Despite the absence of transplacental transfer of CSF-1, similar densities of F4/80-positive cells were evident at birth and during the first postnatal week in $\text{csfm}^{op}$ born to $\text{csfm}^{op}$ females (Fig 4B) as in those born to phenotypically normal $\text{csfm}^{op}$ females.

---

**Fig 2.** Appearance of F4/80-positive cells in fetal and neonatal liver. Tissues were stained for F4/80, a macrophage-specific marker, as described in the Materials and Methods and positive cells were quantified. Results are expressed as the mean ± SEM for $+/\text{csfm}^{op}$ (•) and $\text{csfm}^{op}/\text{csfm}^{op}$ (△) offspring after matings of (A) $+/\text{csfm}^{op}$ female × $\text{csfm}^{op}/\text{csfm}^{op}$ male and (B) $\text{csfm}^{op}/\text{csfm}^{op}$ female × $+/\text{csfm}^{op}$ male mice, respectively. Where indicated, $+/\text{csfm}^{op}$ differed from $\text{csfm}^{op}/\text{csfm}^{op}$ at *P < .001. Results of multiple comparisons over time, where indicated, showed $aP < .01$ and $bP < .001$ versus day 13; $cP < .05$, $dP < .025$, $eP < .01$, and $fP < .001$ versus day 14; $gP < .01$ and $hP < .001$ versus day 15; $iP < .005$ and $jP < .001$ versus day 18; and $kP < .005$ and $lP < .001$ versus postnatal day 1, respectively.

**Fig 3.** F4/80-positive cells in neonatal tissues. Neonatal tissues (postnatal day 7) were stained for the macrophage marker, F4/80, as described in Fig 2, and counterstained with hematoxylin in liver (a and b), spleen (c and d), kidney (e and f), and lung (g and h) of $+/\text{csfm}^{op}$ (a, c, e, and g) and $\text{csfm}^{op}/\text{csfm}^{op}$ (b, d, f, and h) newborn mice born to $+/\text{csfm}^{op}$ mothers. Original magnifications are ×110 (a through f) and ×230 (g and h), respectively. Bar = 50 μm.
Furthermore, although F4/80-positive cells were present in significantly lower numbers in csfmop/csfmop mice born to csfmop/csfmop mothers compared with 1/csfmop littermates (Fig 4B), they nevertheless were present in similar numbers to those seen in csfmop/csfmop born to 1/csfmop females.

On histological examination, differences were evident between csfmop/csfmop and 1/csfmop fetal/neonatal mouse spleens independent of the maternal genotype (Fig 3c and d and data not shown). Splenic F4/80-positive cells were located exclusively in the red pulp and were both stellate and rounded in 1/csfmop mice (Fig 3c). In addition to the reduction in density, F4/80-positive cells in csfmop/csfmop spleen were predominantly rounded cells (Fig 3d).

Kidney. During fetal life, there were minimal to no F4/80-positive cells in the kidneys of csfmop/csfmop mice born to either csfmop/csfmop or 1/csfmop mothers (Fig 5). However, postnatally, the densities were higher at birth and continued to increase over the first week of life in these same mice (Fig 5). In contrast, there was a virtual absence of F4/80-positive cells in kidneys of csfmop/csfmop mice born to both 1/csfmop (Fig 5A) and csfmop/csfmop (Fig 5B) mothers. Consequently, there were many more F4/80-positive macrophages in 1/csfmop compared with csfmop/csfmop kidneys throughout early postnatal development (Fig 5).

Histologic examination showed no obvious effect of maternal genotype on morphology of renal F4/80-positive macrophages, which for the most part are located in the renal medulla and primarily line collecting tubules in 1/csfmop mice (Fig 3e). In csfmop/csfmop mice, they are virtually absent (Fig 3f).

Lung. Similar to the kidney, there was a virtual absence of F4/80-positive cells in the lung of csfmop/csfmop mice born to either csfmop/csfmop or 1/csfmop mothers (Fig 6A). However, postnatally, densities were higher at birth and continued to increase over the first week of life in these same mice (Fig 6A). In contrast, 1/csfmop-positive cells were present during fetal life in 1/csfmop mice born to either maternal genotype (Fig 6A and B). Whereas there was a clear increase in lung macrophages during the first postnatal week in 1/csfmop offspring (Fig 6A), technical difficulties in preserving lung macrophages during the fixation process in csfmop/csfmop offspring beyond 1 day of age limited the ability to draw any conclusions regarding later development.
time points (Fig 6B). Nevertheless, the differences between mutant mice and their normal littermates were readily detectable shortly after birth.

Examination of microscopic sections showed that, in developing lungs (Fig 3h), there were marked reductions in both interstitial and alveolar macrophages, which were present in the corresponding developing tissue (Fig 3g).

**DISCUSSION**

Growth factors that are capable of crossing the placenta during gestation, as we have demonstrated for CSF-1 in this report, have the potential to exert significant effects on developing fetal cell populations. Homologous CSF-1, radiolabeled to high specific activity and administered to pregnant mice in trace quantities that do not disturb steady-state concentrations, is detectable in fetal tissues and serum shortly after injection. The presence of radioactivity in fetal tissues and serum associated not only with intact but also degraded CSF-1 is consistent with previous data, in which we demonstrated that a large proportion of injected labeled CSF-1 is taken up rapidly by the liver, in the present case that of the pregnant mother, and rapidly degraded in that organ and released back into the bloodstream. Furthermore, use of pharmacologic doses of heterologous (human) CSF-1, which is capable of interacting with mouse CSF-1 receptors and is detectable by an RIA that specifically detects biologically active human CSF-1 and not mouse CSF-1, confirms the transplacental passage of this hematopoietic growth factor, which can then potentially interact with CSF-1 receptor bearing fetal cells. These data are similar to those reported for G-CSF, which is detectable in the fetal circulation within minutes after maternal administration. Furthermore, as in the case of CSF-1 in this report, fetal levels of G-CSF were far lower than maternal levels. Nevertheless, significant effects were still observed on fetal myelopoiesis.

The csfmop/csfmop mouse is well suited for the study of the requirements of different tissues for circulating versus locally produced CSF-1 for the establishment of mononuclear phago-
cyte populations. Although the presence of biologically active concentrations of both the proteoglycan and glycoprotein forms of CSF-1 in the circulation and of biologically active cell surface-associated CSF-1 glycoprotein have been described in normal animals, none of these species can be detected in csfmo/csfmop mice. Previous data on the postnatal administration of exogenous CSF-1 to csfmo/csfmop mice suggest that the response of mononuclear phagocytes to circulating growth factor is tissue specific, with complete restoration in tissues such as liver, spleen, and kidney; partial restoration in gastrointestinal tissues, bladder, salivary glands, and dermis; and no effect in muscle, synovium, and tendon. Thus, although in some tissues regulation of mononuclear phagocyte production may be mediated by circulating CSF-1, in others, it may require growth factor locally, as either the cell surface form or the sequestered proteoglycan.

In the current report, differences between +/csfmo and csfmo/csfmop animals in the appearance of F4/80-positive mononuclear phagocytes suggest that CSF-1 is responsible for the perinatal development of a very large proportion of mononuclear phagocytes in the liver, spleen, kidney, and lung. Furthermore, the ability of maternally derived circulating CSF-1 to compensate for the total absence of local CSF-1 production during fetal and early neonatal life is tissue specific. This phenomenon is most striking in the liver, in which the densities of F4/80-positive cells are equivalent shortly after birth in +/csfmo and csfmo/csfmop mice born to +/csfmo mothers, but not in similar littermate pairs born to csfmo/csfmop mothers. Thus, circulating CSF-1, which is present in normal concentrations in phenotypically normal +/csfmo females, appears to be capable of crossing the placenta and promoting the normal appearance of hepatic mononuclear phagocytes in their csfmo/csfmop offspring. This observation is not so surprising, because nearly 80% of hepatic blood flow in the fetus...
CSF-1 AND MONONUCLEAR PHAGOCYTE DEVELOPMENT

3781

mononuclear phagocytes in the liver, kidney, and spleen shortly after birth (postnatal day 1) agree very well with those of Cecchini et al.16 (postnatal day 2). Based on a combination of our data and that of those investigators, it is apparent that, in these tissues, the density of mononuclear phagocytes peaks at 1 week of age (current report) and that, by 2 weeks,16 it has already begun to decrease.

Although the current data point to the importance of CSF-1 in mononuclear phagocyte development, they also suggest that other factors are involved. For example, the data on both hepatic and splenic mononuclear phagocytes, demonstrating the appearance of substantial numbers of cells despite the total absence of CSF-1, are compatible with the involvement of other hematopoietic growth factors or a growth factor-independent pathway for mononuclear phagocyte development. However, from the experiments described here, it is impossible to determine whether such pathways are compensatory, depending on factors other than CSF-1 that operate exclusively in its absence, or normal, in that they operate even when CSF-1 is available in +/csfmpop mice. The degree to which such pathways are operative may be responsible in part for the increased density of F4/80-positive cells in fetal liver of +/csfmpop mice developing in csfmpop mothers relative to those developing in +/csfmpop mothers as well as the increase in F4/80-positive cells seen in postnatal livers of csfmpop mice born to csfmpop mothers allowing them to achieve a similar percentage of positive cells relative to +/csfmpop littersmates at 1 week of age. Previous data suggest that this cell compartment develops under the influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) in addition to CSF-1.24 Although exogenous GM-CSF corrects many of the macrophage deficiencies in csfmpop mice, it is still unable to induce osteoclast production and thereby correct the underlying osteopetrosis.45 Furthermore, mice that are doubly deficient in GM-CSF and CSF-1 still have substantial numbers of mononuclear phagocytes, suggesting that a significant contribution to production of these cells may derive from other factors, such as IL-3 and IL-2/IL-4, the inducible production of which is elevated in mice. Thus, it appears that mononuclear phagocyte production will occur to the greatest degree in the presence of CSF-1 even in the absence of both GM-CSF and IL-3 activity, as demonstrated in mice with inactive receptors for GM-CSF and IL-5 (due to a mutation in their common β chain) and with a targeted inactivating mutation in the IL-3 gene, which have normal numbers of mononuclear phagocytes.47 However, when CSF-1 is absent, even when GM-CSF and IL-3 are both present, as is the case in the csfmpop mouse, mononuclear phagocyte production occurs, but to a much reduced level. Finally, when IL-3 alone of the three mononuclear phagocyte growth factors is present, as in the case of the mouse doubly deficient for CSF-1 and GM-CSF, development of this cell compartment occurs to even a lesser degree and possibly under the additional influence of as yet undetermined additional factors. It is possible that each factor is capable of stimulating a particular subpopulation of target cells and may take on different relative importance in the face of deficiencies of the other respective mononuclear phagocyte growth factors. Specific in situ data may be helpful in elucidating the contributions of these other potential factors in the

Interestingly, our data on the density of F4/80-positive cells in fetal tissues, including the spleen, kidney, and lung.

In contrast to the liver, splenic F4/80-positive cells were reduced by similar proportions in csfmpop compared with +/csfmpop littersmates, regardless of whether they were born to csfmpop or +/csfmpop mothers, reflecting the failure of transplacental CSF-1 to significantly alter F4/80-positive cell density. Whereas the subnormal but substantial development of mononuclear phagocytes in the spleen is consistent with the partial ability of circulating CSF-1 to restore this population,16 the near total absence of F4/80-positive cells in the developing perinatal csfmpop kidney and lung intimate that local CSF-1 production is required for their development. Unlike postnatal restoration of circulating CSF-1 concentrations through exogenous administration, which readily increased the densities of splenic and kidney F4/80-positive cells to normal levels,16 circulating maternal CSF-1 was unable to effect similar results.

Unlike the liver, blood flow to the spleen in utero is derived from the descending aorta distal to the ductus arteriosus and thus consists of a mixture of relatively enriched umbilical vein/ductus venosus and depleted fetal venous return blood.44 Consequently, the spleen may be exposed to CSF-1 concentrations substantially lower than those achieved in the experiments described by Cecchini et al.16 In fact, those investigators demonstrated substantially lower than those achieved in the experiments described by Cecchini et al.16 In fact, those investigators demonstrated a requirement for the establishment of supraphysiologic concentrations of growth factor to fully restore the spleen. However, this requirement was not the case in the kidney, which was extremely responsive to restoration of its mononuclear phagocyte populations by lower doses of exogenous CSF-1 in their experiments.16 The apparent discrepancy between this observation and the failure of maternally derived circulating CSF-1 to promote macrophage development in this tissue during fetal life may actually be attributed to alterations in renal blood flow that occur postnatally. During fetal life, not only does the kidney receive its blood supply via the postdental descending aorta, but it also is characterized by markedly elevated vascular resistance. As a result, the kidney receives approximately 2% of cardiac output in utero compared with the 15% to 18% it receives postnatally.45 Thus, under these conditions, perinatal kidney macrophages appear to depend on local production of CSF-1 for their development. Similar to the kidney, the lung receives a far smaller proportion of cardiac output during fetal life (5% to 10%) compared with postnatal life. Whereas no data exist regarding the responsiveness of lung mononuclear phagocytes to postnatal administration of exogenous CSF-1, our data clearly indicate that, in the absence of local CSF-1 production, the available maternally derived circulating CSF-1 fails to foster the development of either interstitial or alveolar macrophages in this tissue. Finally, with the emergence of the fetal mononuclear phagocyte population in the liver, it would be expected that these cells would play an increasing role in clearance of growth factor from the circulation as it makes its first pass through the fetal circulation, thereby reducing the amount of growth factor available to other fetal tissues, including the spleen, kidney, and lung.
absence of local CSF-1 expression or the total absence of all CSF-1 expression, respectively.

REFERENCES


33. Das SK, Stanley ER, Guilbert LJ, Forman LW: Discrimination of
a colony stimulating factor subclass by a specific receptor on a macrophage cell line. J Cell Physiol 104:359, 1980


44. Koike K, Stanley ER, Ihle JN, Ogawa M: MΦ colony formation supported by purified CSF-1 and/or interleukin-3 in serum-free culture: Evidence for hierarchical difference in MΦ colony forming cells. Blood 67:859, 1986


The Effects of Colony-Stimulating Factor-1 on the Distribution of Mononuclear Phagocytes in the Developing Osteopetrotic Mouse

Philip Roth, Melissa G. Dominguez and E. Richard Stanley